梓醇:一种具有抗癌发展潜力的环烯醚萜苷——综述。

IF 6.3 2区 医学 Q1 CHEMISTRY, MEDICINAL
Lucas Fornari Laurindo, Victória Dogani Rodrigues, Elen Landgraf Guiguer, Lívia Fornari Laurindo, Debora Aparecida Pires de Campos Zuccari, Claudia Rucco Penteado Detregiachi, Adriano Cressoni Araújo, Jéssica da Silva Camarinha Oliveira, Durvanei Augusto Maria, Jefferson Aparecido Dias, Rose Eli Grassi Rici, Caroline Barbalho Lamas, Rosa Direito, Sandra Maria Barbalho
{"title":"梓醇:一种具有抗癌发展潜力的环烯醚萜苷——综述。","authors":"Lucas Fornari Laurindo, Victória Dogani Rodrigues, Elen Landgraf Guiguer, Lívia Fornari Laurindo, Debora Aparecida Pires de Campos Zuccari, Claudia Rucco Penteado Detregiachi, Adriano Cressoni Araújo, Jéssica da Silva Camarinha Oliveira, Durvanei Augusto Maria, Jefferson Aparecido Dias, Rose Eli Grassi Rici, Caroline Barbalho Lamas, Rosa Direito, Sandra Maria Barbalho","doi":"10.1002/ptr.70057","DOIUrl":null,"url":null,"abstract":"<p><p>Catalpol, a natural iridoid glycoside known for its anti-proliferative effects, has been proposed as an anticancer compound. Catalpol targets critical processes involved in cancer cell progression, like malignant proliferation, apoptosis, and metastasis. Additionally, catalpol presents potent anti-inflammatory and antioxidant properties crucial for cancer prevention and intervention. Due to the absence of clinical trials, this review investigates twelve studies, encompassing in vitro and animal trials from reputable databases, such as PubMed, with no time restrictions. Therefore, we covered evidence from catalpol's effects against several types of cancer, including breast, liver, colorectal, lung, gastric, bladder, and ovarian cancer, as well as osteosarcoma, and assessed various outcomes related to cell viability, apoptosis, migration, and modulation of molecular mechanisms by catalpol. Notably, catalpol induced cancer cell death via induction of mitochondrial apoptosis pathways, regulation of the expression of specific microRNAs, modulation of Sirt1, Kras, RACK1, PARP, PI3K/Akt, Bcl-2, and STAT3/JAK2/Src signaling pathways, and inactivation of NF-kB and Smad 2/3 signaling pathways. Furthermore, catalpol limits cancer metastasis due to modulation of critical metalloproteinases associated with cancer migration. Catalpol also synergizes with chemotherapeutic and adjuvant agents to induce cancer control, including regorafenib in liver cancer and chloroquine in gastric cancer, promoting increased anticancer action via upregulated cancer cell apoptosis, decreased proliferation, and inhibited angiogenesis via PI3K/p-Akt/mTOR/NF-κB, VEGF/VEGFR2, and Bax signaling pathways modulation. Catalpol derivatives also gained attention. Pyrazole-, imidazole-, and hydrolyzed-based catalpol derivatives increase cancer cell apoptosis and death and decrease tumor angiogenesis through similar pathways. This review seeks to provide understanding of catalpol's anticancer effects, its mechanisms of action, and its potential as a therapeutic anticancer agent while advocating for future research conductance.</p>","PeriodicalId":20110,"journal":{"name":"Phytotherapy Research","volume":" ","pages":""},"PeriodicalIF":6.3000,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Catalpol: An Iridoid Glycoside With Potential in Combating Cancer Development and Progression-A Comprehensive Review.\",\"authors\":\"Lucas Fornari Laurindo, Victória Dogani Rodrigues, Elen Landgraf Guiguer, Lívia Fornari Laurindo, Debora Aparecida Pires de Campos Zuccari, Claudia Rucco Penteado Detregiachi, Adriano Cressoni Araújo, Jéssica da Silva Camarinha Oliveira, Durvanei Augusto Maria, Jefferson Aparecido Dias, Rose Eli Grassi Rici, Caroline Barbalho Lamas, Rosa Direito, Sandra Maria Barbalho\",\"doi\":\"10.1002/ptr.70057\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Catalpol, a natural iridoid glycoside known for its anti-proliferative effects, has been proposed as an anticancer compound. Catalpol targets critical processes involved in cancer cell progression, like malignant proliferation, apoptosis, and metastasis. Additionally, catalpol presents potent anti-inflammatory and antioxidant properties crucial for cancer prevention and intervention. Due to the absence of clinical trials, this review investigates twelve studies, encompassing in vitro and animal trials from reputable databases, such as PubMed, with no time restrictions. Therefore, we covered evidence from catalpol's effects against several types of cancer, including breast, liver, colorectal, lung, gastric, bladder, and ovarian cancer, as well as osteosarcoma, and assessed various outcomes related to cell viability, apoptosis, migration, and modulation of molecular mechanisms by catalpol. Notably, catalpol induced cancer cell death via induction of mitochondrial apoptosis pathways, regulation of the expression of specific microRNAs, modulation of Sirt1, Kras, RACK1, PARP, PI3K/Akt, Bcl-2, and STAT3/JAK2/Src signaling pathways, and inactivation of NF-kB and Smad 2/3 signaling pathways. Furthermore, catalpol limits cancer metastasis due to modulation of critical metalloproteinases associated with cancer migration. Catalpol also synergizes with chemotherapeutic and adjuvant agents to induce cancer control, including regorafenib in liver cancer and chloroquine in gastric cancer, promoting increased anticancer action via upregulated cancer cell apoptosis, decreased proliferation, and inhibited angiogenesis via PI3K/p-Akt/mTOR/NF-κB, VEGF/VEGFR2, and Bax signaling pathways modulation. Catalpol derivatives also gained attention. Pyrazole-, imidazole-, and hydrolyzed-based catalpol derivatives increase cancer cell apoptosis and death and decrease tumor angiogenesis through similar pathways. This review seeks to provide understanding of catalpol's anticancer effects, its mechanisms of action, and its potential as a therapeutic anticancer agent while advocating for future research conductance.</p>\",\"PeriodicalId\":20110,\"journal\":{\"name\":\"Phytotherapy Research\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":6.3000,\"publicationDate\":\"2025-09-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Phytotherapy Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/ptr.70057\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Phytotherapy Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/ptr.70057","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

摘要

梓醇是一种天然环烯醚萜苷,以其抗增殖作用而闻名,已被提出作为抗癌化合物。梓醇靶向肿瘤细胞进展的关键过程,如恶性增殖、凋亡和转移。此外,梓醇还具有抗炎和抗氧化的特性,对癌症的预防和干预至关重要。由于缺乏临床试验,本综述调查了12项研究,包括来自PubMed等知名数据库的体外和动物试验,没有时间限制。因此,我们涵盖了梓醇对几种类型癌症(包括乳腺癌、肝癌、结肠直肠癌、肺癌、胃癌、膀胱癌和卵巢癌以及骨肉瘤)的作用的证据,并评估了梓醇与细胞活力、凋亡、迁移和分子机制调节相关的各种结果。值得注意的是,梓醇通过诱导线粒体凋亡通路、调节特定microrna的表达、调节Sirt1、Kras、RACK1、PARP、PI3K/Akt、Bcl-2和STAT3/JAK2/Src信号通路以及NF-kB和Smad 2/3信号通路的失活来诱导癌细胞死亡。此外,梓醇通过调节与癌症迁移相关的关键金属蛋白酶来限制癌症转移。Catalpol还与化疗和辅助药物协同诱导癌症控制,包括肝癌中的reorafenib和胃癌中的氯喹,通过上调癌细胞凋亡,减少增殖,并通过PI3K/p-Akt/mTOR/NF-κB, VEGF/VEGFR2和Bax信号通路调节抑制血管生成,从而促进抗癌作用的增强。梓醇衍生物也引起了人们的注意。吡唑、咪唑和水解的梓醇衍生物通过类似的途径增加癌细胞凋亡和死亡,减少肿瘤血管生成。本综述旨在提供对梓醇的抗癌作用、作用机制及其作为治疗性抗癌药物的潜力的理解,同时为未来的研究提供支持。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Catalpol: An Iridoid Glycoside With Potential in Combating Cancer Development and Progression-A Comprehensive Review.

Catalpol, a natural iridoid glycoside known for its anti-proliferative effects, has been proposed as an anticancer compound. Catalpol targets critical processes involved in cancer cell progression, like malignant proliferation, apoptosis, and metastasis. Additionally, catalpol presents potent anti-inflammatory and antioxidant properties crucial for cancer prevention and intervention. Due to the absence of clinical trials, this review investigates twelve studies, encompassing in vitro and animal trials from reputable databases, such as PubMed, with no time restrictions. Therefore, we covered evidence from catalpol's effects against several types of cancer, including breast, liver, colorectal, lung, gastric, bladder, and ovarian cancer, as well as osteosarcoma, and assessed various outcomes related to cell viability, apoptosis, migration, and modulation of molecular mechanisms by catalpol. Notably, catalpol induced cancer cell death via induction of mitochondrial apoptosis pathways, regulation of the expression of specific microRNAs, modulation of Sirt1, Kras, RACK1, PARP, PI3K/Akt, Bcl-2, and STAT3/JAK2/Src signaling pathways, and inactivation of NF-kB and Smad 2/3 signaling pathways. Furthermore, catalpol limits cancer metastasis due to modulation of critical metalloproteinases associated with cancer migration. Catalpol also synergizes with chemotherapeutic and adjuvant agents to induce cancer control, including regorafenib in liver cancer and chloroquine in gastric cancer, promoting increased anticancer action via upregulated cancer cell apoptosis, decreased proliferation, and inhibited angiogenesis via PI3K/p-Akt/mTOR/NF-κB, VEGF/VEGFR2, and Bax signaling pathways modulation. Catalpol derivatives also gained attention. Pyrazole-, imidazole-, and hydrolyzed-based catalpol derivatives increase cancer cell apoptosis and death and decrease tumor angiogenesis through similar pathways. This review seeks to provide understanding of catalpol's anticancer effects, its mechanisms of action, and its potential as a therapeutic anticancer agent while advocating for future research conductance.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Phytotherapy Research
Phytotherapy Research 医学-药学
CiteScore
12.80
自引率
5.60%
发文量
325
审稿时长
2.6 months
期刊介绍: Phytotherapy Research is an internationally recognized pharmacological journal that serves as a trailblazing resource for biochemists, pharmacologists, and toxicologists. We strive to disseminate groundbreaking research on medicinal plants, pushing the boundaries of knowledge and understanding in this field. Our primary focus areas encompass pharmacology, toxicology, and the clinical applications of herbs and natural products in medicine. We actively encourage submissions on the effects of commonly consumed food ingredients and standardized plant extracts. We welcome a range of contributions including original research papers, review articles, and letters. By providing a platform for the latest developments and discoveries in phytotherapy, we aim to support the advancement of scientific knowledge and contribute to the improvement of modern medicine.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信